We use cookies to ensure that we give you the best experience on our website Learn more

My documents

Sep 13, 2018

ERC congress - Resuscitation 2018

5 - Cardioversion for atrial fibrillation: Efficacy of dose-response of low energy, high energy and pulsed biphasic truncated exponential waveforms

Abstract

Abstract

thumbnail

Keywords

Abstract

Introduction: The evolution of defibrillation waveforms has dramatically progressed over time. Monophasic waveform became the standard waveform used in most defibrillators until the 1980s, and were progressively replaced after year 2000 by newer biphasic waveforms with different patterns: initially the biphasic rectilinear waveform, then biphasic truncated exponential (BTE) waveform with High Energy (HE) or Low Energy (LE) or Pulsed Energy (PE). Aim: Our aim was to collect data regarding the efficacy of low, high and pulsed energy of biphasic truncated exponential waveforms, in cardioversion of atrial fibrillation through a systematic research on the literature. Methods: A systematic research on PubMed and Science Direct, with key words (cardioversion atrial fibrillation biphasic waveform) and filters (title/abstract, clinical trial, English) provided 38 articles. A further selection was made by their title and abstract leading to a final selection of 6 articles. Efficacy was defined as return to sinus rhythm. Results: The graphic provides cumulative shock success versus cumulative energy for different BTE waveforms: 4 High Energy (HE), 3 Low Energy (LE) and 3 Pulsed Energy (PE). Legend of the graphic indicates for each study the year of publication, the recruitment period, the sample size, the delay between cardioversion and observed rhythm, and the percentage of patients in atrial flutter when appropriate. Although the studies present major disparities, the efficacy concentrates within 85% and 95%. Conclusion: During cardioversion of atrial fibrillation, cumulative shock success of high, low or pulsed energy biphasic truncated exponential waveforms are rather similar, with efficacy at last shock ranging between 85% and 95%.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.